PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY (PACTG)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项前瞻性研究，旨在描述目前用于妊娠HIV感染妇女临床护理的部分抗逆转录病毒药物在妊娠期的药代动力学参数，并确定这些抗逆转录病毒药物的治疗剂量制度是否会产生足够的孕期药物暴露，与a)来自非怀孕成年人的历史数据；以及b)研究队列中的相同妇女在产后时期。第二个目标是比较分娩时脐血中抗逆转录病毒药物在母体血浆中的浓度，并通过测定6B-羟基皮质醇与皮质醇的比例来间接评估细胞色素P450 3A4的诱导。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a prospective study to describe the pharmacokinetic parameters during pregnancy of selected antiretroviral drugs currently used in the clinical care of pregnant HIV infected women, and to determine if therapeutic dosing regimes of these antiretroviral drugs produce adequate drug exposure during pregnancy compared to a) historical data from non-pregnant adults; and b) the same women in the study cohorts during the post-partum period. The secondary objectives are to compare antiretroviral drug concentrations in plasma from cord blood in those in maternal plasma at the time of delivery and to indirectly assess the induction of cytochrome P450 3A4 by determinie the ratio in ruine of 6B-hydroxycortisol to cortisol.